Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development
Search Refinements
Search Results: Drug Discovery & Development
1-15 of 5039 results
QB3@953 signs collaboration agreement with GSK to identify early-stage drug discovery opportunities
QB3@953, a San Francisco incubator created by QB3, a University of California (UC) research institute and biotech accelerator, announced an agreement with pharmaceutical company GSK to identify and facilitate collaborations to translate early drug target concepts into medicines that benefit patients.
Drug Research > Drug Discovery & Development > News
Bristol-Myers, QIMR to discover new immuno-oncology antibodies
By PBR Staff Writer
Bristol-Myers Squibb (BMS) has entered into a research collaboration and license agreement with QIMR Berghofer Medical Research Institute for the discovery of new therapeutic antibodies against an undisclosed immuno-oncology (I-O) target.
Drug Research > Drug Discovery & Development > News
Soligenix gets additional NIAID funding to advance development of OrbeShield in GI ARS
Soligenix (SNGX), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised its option to advance preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP).
Drug Research > Drug Discovery & Development > News
Symic Biomedical gets $1.5m NIH Phase II SBIR grant to develop proteoglycan mimetic therapeutics
Platform therapeutic company Symic Biomedical (Symic) announced that it has received a $1.5m Phase II SBIR grant from the National Institutes of Health (NIH) to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis.
Drug Research > Drug Discovery & Development > News
Ironshore begins second Phase III trial of HLD-200 in pediatric ADHD patients
By PBR Staff Writer
Canada-based Highland Therapeutics' subsidiary Ironshore Pharmaceuticals has started dosing in the second of two pivotal trials of HLD-200, a next-generation formulation of methylphenidate for patients with attention-deficit/hyperactivity disorder (ADHD).
Drug Research > Drug Discovery & Development > News
HedgePath launches clinical trial for proposed cancer treatment
HedgePath Pharmaceuticals (HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced enrollment has commenced in its Phase II SCORING (SUBA-Cap Objective Response in Gorlin's) clinical trial.
Drug Research > Drug Discovery & Development > News
Vital Therapies' Phase III trial of ELAD System in patients with AILD failed to meet primary endpoint
Vital Therapies (VTL), a biotherapeutic company developing ELAD, a cell-based therapy targeting the treatment of liver failure, today announced that topline results from VTI-208, the Company's phase 3 randomized, controlled, open-label trial, evaluating the ELAD System in subjects with alcohol-induced liver decompensation (AILD) failed to meet the primary endpoint of overall survival through at least 91 days assessed using the Kaplan Meier statistical method.
Drug Research > Drug Discovery & Development > News
Roche and Janus partner to develop TLR inhibitor for autoimmune diseases
By PBR Staff Writer
Swiss drugmaker Roche has partnered with Janus Biotherapeutics to develop a small molecule toll-like receptor (TLR) inhibitor with the potential to address various autoimmune diseases.
Drug Research > Drug Discovery & Development > News
BioLineRx begins Phase IIb trial of new AML consolidation treatment BL-8040
By PBR Staff Writer
Israeli biopharmaceutical firm BioLineRx has started a Phase IIb trial for BL-8040 as a new consolidation treatment for patients with acute myeloid leukemia (AML).
Drug Research > Drug Discovery & Development > News
Pfenex wins $143.5m BARDA contract to develop new anthrax vaccine
By PBR Staff Writer
US-based biotechnology firm Pfenex has secured a five-year $143.5m contract from the biomedical research arm of the US Department of Health and Human Services (HHS) to develop Px563L, a mutant recombinant protective antigen (rPA) anthrax vaccine.
Drug Research > Drug Discovery & Development > News
Chemoswed becomes Chemoswed
It has been broadly announced, that DuPont made a decision to separate the Performance Chemicals segment, creating two strong, independent companies by mid-2015.
Drug Research > Drug Discovery & Development > Press Releases
Renewed GMP Certificate
Following inspections which took place late 2014, Chemoswed has received an updated certificate of GMP compliance. The certificate was issued by the Swedish Medical Products Agency, and covers all manufacturing facilities, i. e. kilolab, pilot plant, and the main manufacturing plant.
Drug Research > Drug Discovery & Development > Press Releases
Sydney researchers advance drug discovery for melanoma treatment
By PBR Staff Writer
Researchers at the Centenary Institute at the University of Sydney have advanced the development of a new class of drugs for the treatment of certain cases of melanoma.
Drug Research > Drug Discovery & Development > News
CMC Biologics, PATH Malaria Vaccine Initiative to develop new monoclonal antibodies
By PBR Staff Writer
CMC Biologics has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test their capacity to protect humans from malaria infection.
Drug Research > Drug Discovery & Development > News
Neuropore begins Phase 1 clinical trials with NPT200-11 to treat Parkinson’s disease
By PBR Staff Writer
US-based Neuropore Therapies has started Phase I clinical trials with NPT200-11, a new potential treatment for Parkinson’s disease (PD).
Drug Research > Drug Discovery & Development > News

PBR Supplier Recommendations

Therapure Biopharma - Contract Protein Development and Manufacturing
Therapure Biopharma is a Contract Development and Manufacturing Organization (CDMO) that specializes in the development, scale up and manufacture of complex biologics. ... Drug Research > Drug Discovery & Development > Suppliers
Vetter Pharma International - High-Quality Aseptically Pre-Filled Injection Systems
From preclinical development through commercial supply.... Drug Research > Drug Discovery & Development > Suppliers
ERT - Getting it done. Right.
ERT is a leading global provider of high-quality patient safety and efficacy endpoint data collection solutions for use by biopharmaceutical companies during clinical drug development. ERT delivers a combination of technology, services, and consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle.... Drug Research > Drug Discovery & Development > Suppliers
Eppendorf - We Know Bioprocessing
Eppendorf is a leading life science company that develops and sells instruments, consumables, and services for liquid-, sample-, and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers, and DNA amplification equipment as well as ultra-low temperature freezers, fermentors, bioreactors, CO² incubators, shakers, and cell manipulation systems. Consumables such as pipette tips, test tubes, microtiter plates, and disposable bioreactors complement the range of highest-quality premium products.... Drug Research > Drug Discovery & Development > Suppliers
Biovian - cGMP Contract Manufacturing of Biopharmaceuticals
Biovian is a dynamic and effective new generation one-stop-shop CMO in cGMP contract manufacturing of biopharmaceuticals. Biovian's services cover the full range from antigen isolation, expression, vector construction, cell line cultivation, cGMP protein purification to product fill and finish.... Drug Research > Drug Discovery & Development > Suppliers
See more

PBR White Paper Recommendations

Truly Parallel - Microbiology By Eppendorf
DASGIP® Bioreactor Systems for Microbiology.... Drug Research > Drug Discovery & Development > White Papers Truly Parallel - Cell Culture By Eppendorf
DASGIP® Bioreactor Systems for Cell Culture Applications.... Drug Research > Drug Discovery & Development > White Papers Product Brochure: Most Compact By Eppendorf
DASbox® Mini Bioreactor System for Cell Culture and Microbiology.... Drug Research > Drug Discovery & Development > White Papers Product Brochure: The Smarter Solution By Eppendorf
BioFlo® 320 bioprocess control station.... Drug Research > Drug Discovery & Development > White Papers All-Purpose Protein Sample QC Using a Novel Micro-Volume Platform with Spectral Content Profiling Software By Trinean
Accurate total protein quantitation of purified proteins, cell lysates, affinity-column fractions or other complex protein samples is crucial for robust biochemical testing during biopharmaceutical development as well as production. As the presence of chemicals doesn't allow simple A280 protein quantification, more labor-intensive alternatives for quantification are used. Examples are the colorimetric Bradford or BCA assay, which negate to a large extent the presence of contaminants but require multiple steps and show variation depending on the sample composition and time point of measuring within the ongoing reaction.... Drug Research > Drug Discovery & Development > White Papers See more
1-15 of 5039 results